SCHEMBL25915463

SCHEMBL25915463

CC(C)[C@H](N)C(=O)O[C@H]1[C@@H](O)C[C@](C#N)(c2ccc3c(N)ncnn23)O[C@@H]1COC(=O)CC1CCCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25916612 0.90 TMPRSS2 (0.31) —
SCHEMBL25915389 0.90 TMPRSS2 (0.30) —
SCHEMBL24791223 0.89 TMPRSS2 (0.36) —
SCHEMBL24916962 0.89 TMPRSS2 (0.30) —
SCHEMBL25916196 0.89 TMPRSS2 (0.31) —
SCHEMBL25916424 0.89 TMPRSS2 (0.31) —
SCHEMBL25316075 0.87 TMPRSS2 (0.33) —
SCHEMBL24917020 0.87 TMPRSS2 (0.33) —
SCHEMBL30091014 0.87 TMPRSS2 (0.33) —
SCHEMBL24917121 0.87 TMPRSS2 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-07-27 — — US disclosed
US-11638715-B2 Orally-bioavailable nucleoside analogs VenatoRx Pharmaceuticals, Inc. (US) 2023-05-02 — — US disclosed
Send feedback